PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib

Xiaocui Zhang, Meige Sun, Yisheng Jiao, Bei Lin, and Qing Yang

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China

Correspondence should be addressed to Qing Yang; yangqing sj@126.com

Received 14 May 2022; Revised 9 August 2022; Accepted 16 August 2022; Published 5 September 2022

Academic Editor: Junmin Zhang

Copyright © 2022 Xiaocui Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PHGDH attaches importance to serine biosynthesis in cancer cells and maintaining mitochondrial redox homeostasis. However, the role of PHGDH inhibitor CBR-5884 in cell ROS level and its downstream pathways has not been explored in epithelial ovarian cancer. Thus, we investigated the function and possible mechanism of PHGDH inhibitor CBR-5884 on epithelial ovarian cancer in vitro and in vivo. A2780, OVCAR3, and ES-2 were treated with CBR-5884 at different concentrations or different time points. Results showed that CBR-5884 inhibited epithelial ovarian cancer cell proliferation, migration, and invasion and increases cell ROS level. Meanwhile, CBR-5884 exerts antitumor effect through activating ROS/Wnt/β-catenin pathway. Besides, CBR-5884 exerts antitumor effect in vivo. What’s more, we explored the effect of CBR-5884 with or without PARP inhibitor Olaparib, which showed that the two together had a larger effect. In conclusion, PHGDH inhibitor CBR-5884 inhibits epithelial ovarian cancer proliferation, migration, and invasion through activating ROS/Wnt/β-catenin pathway and plays a synergistic role with PARP inhibitor olaparib, which provided a theoretical basis for PHGDH inhibitor CBR-5884 in clinical treatment.

1. Introduction

As reported, there were 313,959 cases of newly diagnosed ovarian cancer and 207,252 new deaths for OC in 2020 [1]. EOC is the most common type of ovarian cancer, difficult to find and diagnose in the early stage of disease, deficient in choices of treatment, and easy to relapse [2–5]. Therefore, future exploring the mechanism underlying EOC initiation and progression for further exploring biomarkers to diagnose, treat, and predict the prognosis of EOC is of significance to women in the world.

Serine is a raw material to participate in the synthesis of lipids, proteins and nucleotides and an important source of one carbon unit in cells, which is closely related to the metabolic remodeling of tumor cells [6–8]. As the key enzyme in serine biosynthesis pathway, PHGDH attaches importance to maintaining mitochondrial redox homeostasis, maintaining mitochondrial redox homeostasis [9–12]. Mitochondrial serine produces NADPH and GSH reduction equivalents under SHMT2 catalysis, inhibiting the production of ROS [10, 13, 14]. ROS can also promote antitumor signal transmission and initiate oxidative stress-induced tumor cell death, and one of the antitumor mechanisms of cisplatin is to induce apoptosis by increasing the production of ROS in tumor cells [15–17]. In our recent study, we reported that PHGDH is upregulated at translational level and implicated in platin-resistant in epithelial ovarian cancer cells [18]. However, the role of PHGDH in cell ROS level and its downstream pathways has not been explored in epithelial ovarian cancer. CBR-5884 is one kind of PHGDH inhibitor that have been reported and played a tumor suppressing role in breast cancer [19–23].

Reactive oxygen species which are produced by cell metabolic activities attach importance to cell signal transduction and homeostasis and regulate cell proliferation, apoptosis, and differentiation [24–26]. Recent studies suggested that oxidative stress induced by ROS can regulate Wnt/β-catenin signaling pathway in colorectal, breast, lung, pancreatic, and
liver cancer [24, 27–31]. Therefore, studying the effect of CBR-5884 and NAC in the regulation of Wnt/β-catenin pathway is significant.

PARP inhibitors can enhance the efficacy of radiotherapy and chemotherapy with alkylating agents and platinum drugs by inhibiting DNA damage and repair of tumor cells and promoting apoptosis of tumor cells [32]. Olaparib, a kind of PAPR inhibitor, is mainly used to alleviate the maintenance treatment of platinum sensitive adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after platinum containing chemotherapy has achieved complete remission [33–35]. Therefore, it is of significance to explore the effect of CBR-5884 with or without olaparib.

Here, we cultured epithelial ovarian cancer cell lines and constructed tumor xenografts model in nude mouse to evaluate the effect of CBR-5884 on epithelial ovarian cancer in vitro and in vivo. Meanwhile, we studied the role of CBR-5884 in cell ROS level and its downstream pathway as well as the effect of CBR-5884 with or without PARP inhibitor olaparib, which may give us a novel prospect in mechanism and clinical treatment of epithelial ovarian cancer.

2. Materials and Methods

2.1. Materials and Cell Culture. The PHGDH inhibitor CBR-5884, the ROS inhibitor N-acetylcysteine, and the PARP inhibitor olaparib were purchased from MedChemExpress. DMSO was used as control group in cell lines. Through literature reviewing, we used 5 mM NAC treated for 4 h to study its effect [36, 37]. The cell lines (A2780, OVCAR3, and ES-2) were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China). A2780 and OVCAR3 were cultured with RPMI 1640 medium (Procell, Wuhan, China) containing 10% FBS (Procell, Wuhan, China), while ES-2 was cultured used McCoy’s 5A (Procell, Wuhan, China) containing 10% FBS (Procell, Wuhan, China) in incubator. The incubator purchased from PUHE Biotechnology Co., Ltd. (Wuxi, China) was set at 37°C, 5% CO2, and 1% O2 with enough humidity.

2.2. Cell Viability Assay. A total of 5,000 cells/well were added to 96-well plates and incubated in incubator for 24 h. After different treatment measures, 1 μL of CCK-8 test solution (Procell, Wuhan, China) was added to each well and incubated together for 2 h. The microplate reader was used to measure OD450.

2.3. Colony Formation Assay. 1000 cells were plated into each well of 6-well plates. After cultured with different treatment measures for 15 days, 4% paraformaldehyde was used for fixing and 1% crystal violet for staining. Colonies meaning cell count >50 were counted.

2.4. Apoptosis Condition Assay with Flow Cytometry. The cells were collected after different treatment measures and suspended in PBS. Next, the cells were centrifuged at 4°C and 1200 rpm for 5 min, and the supernatant was discarded. Use 100 μL binding buffer to resuspend the cells, add 5 μL Annexin V-FITC and 5 μL PI solution (Procell, Wuhan, China), incubate them in room temperature for 15 mins, and add the other 400 μL binding buffer to the mix. Keep away from light and use flow cytometry to detect.

2.5. Cell Cycle Distribution with Flow Cytometry. The cells were collected after different treatment measures and suspended in PBS. Next, the cells were centrifuged at 4°C and 1200 rpm for 5 min, and the supernatant was discarded. Use 75% ethanol to resuspend the cells and fix them at 4°C overnight. The next day, use PBS to wash the cell precipitation 3 times, resuspend the cells with 500 μL PI/RNase mix (PI 100 μL, RNase 400 μL, Solarbio, Beijing, China) and incubate them together at 37°C for 30 mins. Keep the tube in ice, away from light, and use flow cytometry to detect.

2.6. Transwell Assay. 8-μm-pore transwell chambers coated with or without Matrigel (BD, San Diego, USA) (Corning, NY, USA) were used for cell invasion and migration detection. Put 700 μL 20%-FBS containing medium into each bottom chamber, and cells in FBS-free medium (1.0 × 10^4 cells/200 μL without Matrigel and 3.0 × 10^4 cells/200 μL with Matrigel) were seeded into the upper chamber. After cultured in the incubator for 24 h, suspended cells in the upper chamber were cleaned out, fix the cells attached to the bottom membrane with 4% paraformaldehyde, and stain with crystal violet. The inverted microscope was used to photograph Images at 200× magnification, and the cells were counted using the image J software.

2.7. Cell Oxidative Phosphorylation Level Detection. Cell LDH release level, NADPH level, and GSH level were detected using LDH Cytotoxicity Assay Kit, NADP+/NADPH Assay Kit with WST-8, and GSH and GSSG Assay Kit (Beyotime, Shanghai, China) according to the instructions. Besides, cell ROS level was detected using Reactive Oxygen Species Assay Kit (Beyotime) by flow cytometry.

2.8. Western Blot. RIPA lysate (Beyotime, Shanghai, China) was used to extract the total protein of cells and tumor xenografts according to the instructions. Then, the extracted total protein was separated by 10% SDS/PAGE and transferred to

| Antibody                | Company       | Lot no.  | Dilution ratio |
|-------------------------|---------------|----------|----------------|
| PHGDH                   | Proteintech   | 14719-1-AP | 1:1000         |
| β-Catenin               | Wanleibio     | WL0962a  | 1:1000         |
| c-myc                   | Proteintech   | 10828-1-AP | 1:1000         |
| Cyclin D1               | Wanleibio     | WL01435a | 1:1000         |
| PCNA                    | Proteintech   | 10205-2-AP | 1:1000         |
| Bcl2                    | Proteintech   | 12789-1-AP | 1:1000         |
| BAX                     | Proteintech   | 50599-2-ig | 1:1000         |
| E-cadherin              | Proteintech   | 20874-1-AP | 1:5000         |
| N-cadherin              | Proteintech   | 22018-1-AP | 1:2000         |
| Vimentin                | Proteintech   | 10366-1-AP | 1:2000         |
| Snail                   | Wanleibio     | WL01863  | 1:1000         |
| GAPDH                   | Proteintech   | 10494-1-AP | 1:5000         |
Figure 1: Continued.
Figure 1: Continued.
were used for immunohistochemistry. Following deparaffinization, antigen repair and sealed off, the sections were incubated with antibody against PHGDH (1:200, 14719-1-AP, Proteintech) or Ki67 (1:200, 9027 T, CST) at 4°C overnight. The slides were incubated with biotinylated goat anti-rabbit antibodies for 1.5 h, stained with diaminobenzidine (abs957, Absin Biotechnology Co., Ltd, Beijing, China) and then counterstained with hematoxylin (abs957, Absin Biotechnology Co., Ltd, Beijing, China). The sections were scored according to the percentage of positive staining cells (0 = negative; 1 = 5 – 25%; 2 = 26 – 50%; 3 = 51 – 74%; and 4 = 75 – 100%) and the intensity of staining (0 = no staining; 1 = slight staining; 2 = moderate staining; and 3 = strong staining). Scores for the percentage and intensity of staining were added.

2.9. Animal Study. 10 female BALB/Ca-nu nude mice (Beijing Huafukang Biosciences, Beijing, China) in 2 months were maintained in specific pathogen-free (SPF) conditions. The most common epithelial ovarian cancers are serous, mucinous, endometrioid, and clear cell carcinoma. The most common is serous ovarian cancer. Besides, OVCAR3 is one of the commonly and typically used human cell lines for xenograft models [38, 39]. Therefore, 2 × 10⁶ OVCAR3 cells were suspended in 150 μL PBS and injected subcutaneously into the axilla of mice. Five days after tumor formation, the mice were treated with physiological saline and CBR-5884 (drug concentration 20 mg/kg) by intraperitoneal injection every two days for 10 days. The long and short diameter of tumor were measured every two days, and the tumor volumes are calculated by \( V = \frac{1}{2} \times \text{long diameter} \times \text{short diameter} \). All mice were euthanized 15 days later. The tumor weight was measured. Institutional Animal Research Committee of China Medical University approved the animal study.

2.10. Immunohistochemistry. 5-μm-thick paraffin sections were used for immunohistochemistry. Following deparaffinization, antigen repair and sealed off, the sections were incubated with antibody against PHGDH (1:200, 14719-1-AP, Proteintech) or Ki67 (1:200, 9027 T, CST) at 4°C overnight. The slides were incubated with biotinylated goat anti-rabbit antibodies for 1.5 h, stained with diaminobenzidine (abs957, Absin Biotechnology Co., Ltd, Beijing, China) and then counterstained with hematoxylin (abs957, Absin Biotechnology Co., Ltd, Beijing, China). The sections were scored according to the percentage of positive staining cells (0 = negative; 1 = 5 – 25%; 2 = 26 – 50%; 3 = 51 – 74%; and 4 = 75 – 100%) and the intensity of staining (0 = no staining; 1 = slight staining; 2 = moderate staining; and 3 = strong staining). Scores for the percentage and intensity of staining were added.

2.11. Statistical Analysis. Statistical analysis was conducted by unpaired Student’s t-test in GraphPad Prism 9 (La Jolla, CA, USA). Differences were considered to be statistically significant with \( p < 0.05 \) (*\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \), and ****\( p < 0.0001 \)).

3. Results

3.1. CBR-5884 Inhibits EOC Proliferation, Migration and Invasion. We conducted our experiments using adenocarcinoma A2780, OVCAR3, and adding clear cell carcinoma ES-2, which involved a relatively comprehensive pathological type of epithelial ovarian cancer cell lines. Besides, we downloaded transcriptomic data of 47 ovary cell lines and listed the PHGDH expression level in Supplementary Table 1 and found that the PHGDH expression level of A2780, OVCAR3, and ES-2 was relatively high. Therefore, we chose A2780, OVCAR3, and ES-2 cell lines for future experiments. Then, cell viability of cells treated with different concentration (0, 10, 20, 30, 45, and 60 μM) of CBR-5884.
**Figure 2:** CBR-5884 increases cell ROS level in epithelial ovarian cancer cell lines. (a) LDH release, (b) NADPH, (c) GSH, and (d) ROS level of A2780, OVCAR3, and ES-2 cells after treatment of different concentration of CBR-5884.
Figure 3: Continued.
Figure 3: Continued.
at different time points (12h, 24h, and 48h) was tested (Figure 1(a)). Accordingly, to keep the inhibition rate, CBR-5884 concentration at 0, 15, 30, and 45 μM was used for other experiments in the form of an isochronous sequence. Besides, OVCAR3, A2780, and ES-2 were treated with CBR-5884 for 24h, 48h, and 48h, respectively. The cell proliferation decreased (Figure 1(b)), apoptosis increased (Figure 1(c)), DNA replication attenuated (Figure 1(d)), cell invasion, and migration weakened (Figure 1(e) and 1(f)) after treatment of 0, 15, 30, and 45 μM CBR-5884. In addition, CBR-5884 inhibits EOC proliferation, migration, and invasion in a dose- and time-dependent manner.

3.2 CBR-5884 Increases Cell ROS Level in Epithelial Ovarian Cancer Cell Lines. After treatment of 0, 15, 30, and 45 μM CBR-5884, the cell LDH release increased (Figure 2(a)), NADPH level reduced (Figure 2(b)), GSH level descended (Figure 2(c)), and ROS level heightened (Figure 2(d)).

3.3 CBR-5884 Exerts Tumor Suppression Effect through Increasing Cell ROS Level. To explore whether CBR-5884 inhibits EOC proliferation, migration, and invasion through increasing cell ROS level, we set four group (control group, 5 mM NAC for 4h, 30 μM CBR for 24h in OVCAR3, 48h in A2780 and 48h in ES-2, and 30 μM CBR for 24h in
Figure 4: NAC rescues the effect of CBR-5884 in epithelial ovarian cancer cell lines. (a) LDH release, (b) NADPH, (c) GSH, and (d) ROS level of A2780, OVCAR3, and ES-2 cells after treatment of CBR-5884 with or without NAC.
CBR-5884, 48 h in A2780, and 48 h in ES-2 with 5 mM NAC for 4 h). NAC is an ROS inhibitor.

As shown in Figure 3, NAC promoted EOC malignant biological behavior, CBR-5884 inhibited EOC malignant biological behavior consistent with that in Figure 1, and CBR-5884 together with NAC abolished the tumor suppression effect of CBR-5884.

Additionally, NAC decreased the cell LDH release level (Figure 4(a)), heightened NADPH level (Figure 4(b)), increased GSH level (Figure 4(c)), and reduced ROS level (Figure 4(d)). CBR-5884 promoted the ROS level consistent with that in Figure 2. What’s more, CBR-5884 together with NAC abolished the ROS promoting effect of CBR-5884 (Figures 4(a)–4(d)).

3.4. CBR-5884 Exerts anti-Tumor Effect through Activating ROS/Wnt/β-Catenin Pathway. To further understand the mechanism in drug inhibition of the epithelial ovarian cancer, we detected the downstream molecules changes. As shown in Figure 5, after using 0, 15, 30, and 45 μM CBR-5884, PHGDH and pathway-related indicators β-catenin, c-myc, cyclin D1, PCNA, Bcl2, N-cadherin, vimentin, and Snail expression level declined increasingly, and BAX and E-cadherin ascended increasingly. Besides, NAC promoted expression of PHGDH and pathway related indicators β-catenin, c-myc, cyclin D1, PCNA, Bcl2, N-cadherin, vimentin, and Snail and inhibited expression of BAX and E-cadherin. Meanwhile, CBR-5884 together with NAC abolished the inhibiting effect of CBR-5884 on PHGDH and pathway-related indicators β-catenin, c-myc, cyclin D1, PCNA, Bcl2, N-cadherin, vimentin, Snail, and the promoting effect of CBR-5884 on BAX and E-cadherin (Figure 5).

3.5. CBR-5884 Exerts Antitumor Effect In Vivo. To explore the tumor suppression effect of CBR-5884 in vivo, we used mice xenograft model. Tumor grew more slowly and tumor weight was lighter in group of intraperitoneal injection of CBR-5884 (Figure 6(a)). We also examined the protein level of tumor tissues in two groups, which showed that PHGDH and pathway-related indicators β-catenin, c-myc, cyclin D1, PCNA, Bcl2, N-cadherin, vimentin, and Snail expression level were lower and BAX and E-cadherin higher in CBR-5884 group (Figure 6(d)). The immunohistochemical staining of tumor tissues between two groups showed that PHGDH and Ki67 expressions were inhibited in CBR-5884 group (Figure 6(e)).

3.6. CBR-5884 Plays a Synergistic Role with Olaparib. First, cell viability of cells treated with different concentration (0, 10, 20, 30, 45, and 60 μM) of olaparib at different time points (12 h, 24 h, and 48 h) was tested (Figure 7). As shown in Figure 1, cell viability of OVCAR3, A2780, and ES-2 treated with olaparib for 24 h were approximately 60%-70% inhibited under 60 μM. As shown in Figure 1, cell viability of OVCAR3, A2780, and ES-2 treated with CBR-5884 for 24 h was approximately 60%-70% inhibited under 60 μM, respectively. According to the inhibition rate of OVCAR3, we set CBR and olaparib in a 1:2 concentration ratio (control group, 10 μM olaparib and 20 μM CBR, 20 μM olaparib and 40 μM CBR, and 30 μM olaparib and 60 μM CBR for 24 h in A2780, OVCAR3, and ES-2) to explore the effect of CBR-5884 with or without PARP inhibitor olaparib. And we found that CBR-5884 played a synergistic role in cell viability (Figure 8(a)), proliferation (Figure 8(b)), apoptosis (Figure 8(c)), invasion (Figure 8(e)), and migration (Figure 8(f)) with PARP inhibitor olaparib. However, after using olaparib, cell S phase proportion was increased, and co-effect of CBR-5884 and olaparib abolished the effect of using alone (Figure 8(d)).
Figure 6: Continued.
Figure 6: CBR-5884 exerts anti-tumor effect in vivo. (a) Tumor xenograft, (b) tumor volume, (c) tumor weight, (d) related protein level via WB, and (e) HE staining, PHGDH, and Ki67 expression level via IHC in two groups.

Figure 7: Olaparib inhibits EOC viability. Cell viability condition of A2780, OVCAR3, and ES-2 cells after treatment of different concentration of olaparib.
Figure 8: Continued.
Figure 8: Continued.
4. Discussion

Since EOC causes so many deaths in the world every year, and many patients are suffering from this kind of excruciating disease, it deserves more in-depth exploration and research. Metabolic reprogramming is a mechanism by which cells promote cell proliferation and growth by changing metabolic mode in order to meet energy needs and can be an important marker cell of malignant tumor [40, 41]. Serine synthesis increases in cancer cells and is the third largest metabolic-related substance of cancer cells after glucose and glutamate [6, 8]. PHGDH is the first key enzyme of serine anabolism, which is increased in some tumors and is closely related to poor prognosis [42–44]. Importantly, silencing PHGDH gene can significantly affect the growth of PHGDH-dependent cancer, making the enzyme a new target for cancer treatment [10, 11, 14]. In our recent study, we found that PHGDH was upregulated in epithelial ovarian cancer and was regulated by lncRNA RMRP and DDX3X in translational level [18]. However, how PHGDH affects its downstream pathways remains a question and has not been explored in EOC.

Considering clinical practicability, we used PHGDH inhibitor CBR-5884 to conduct this study. First, we explored the role of CBR-5884 in EOC malignant biological behavior. The results showed that CBR-5884 exerts an antitumor effect. Next, we explored the effect of CBR-5884 on epithelial ovarian cancer cell ROS level. It is reported that cell LDH level, NADPH level, and GSH level could reflect the cell oxidative stress condition and affect cell ROS level [45, 46], so we studied the level of LDH, NADPH, GSH, and ROS. The result showed that CBR-5884 can increase the ROS level, which is consistent with the results that have been reported [22, 47–50]. Thus, we speculated that CBR-5884 exerts an antitumor effect through inducing ROS imbalance in cells.

We added N-acetylcysteine (NAC) to observe whether adding NAC could abolish the tumor suppression effect of CBR-5884. NAC is an ROS inhibitor. If CBR-5884 exerts tumor suppression effect through increasing cell ROS level, then adding NAC could abolish the tumor suppression effect of CBR-5884. As expected, we confirmed that CBR-5884-mediated ROS imbalance was necessary in the tumor suppression effect and that ROS level and CBR-5884 were indeed related and CBR-5884 was highly likely to play a role by affecting intracellular ROS levels. However, there is an interesting phenomenon; when treated with NAC+ CBR, the GSH level in ES-2 cell line is lower than control when it is expected that the GSH level will be higher, which may be because the GSH level in ES-2 cell line is different and specific, which brought us a new perspective to our future research.

Next, we examined the expression level of β-catenin and the pathway-related genes, such as c-myc and Cyclin D1. We also tested the proliferation and apoptosis-related genes, such as BAX, Bcl2, and PCNA. Meanwhile, we tested the EMT-related genes, such as E-cadherin, N-cadherin, vimentin, and Snail. The results showed that CBR-5884 exerts an antitumor effect through activating ROS/Wnt/β-catenin pathway, which is consistent with the reported results in other malignant tumors [24, 27–31]. At last, we verified the effect of CBR-5884 in vivo through nude mice xenograft. The results were consistent with that in vitro. Besides, tumor tissues in CBR-5884 group had lower expression of Ki67, the prognostic indicator commonly used in clinical.

PARP inhibitors represented by olaparib can be used not only for first-line maintenance treatment and second-line
maintenance treatment, but also for post-line rescue treatment, “all online,” with significant curative effect. The studies confirmed that maintenance therapy represented by PARP inhibitors has changed the traditional treatment of epithelial ovarian cancer. Therefore, we explored the effect of CBR-5884 with or without PARP inhibitor olaparib, which showed that the two together had larger effect in cancer inhibition, which gave us a novel idea to clinical therapy. However, after using olaparib, cell S phase proportion was increased, and co-effect of CBR-5884 and olaparib abolished the effect of using alone. Thus, the underlying mechanism of CBR-5884 and olaparib together needs to be further studied. While the safety and effectiveness of combined use also need being tested by clinical trials.

Through our research, we can get a knowledge of the tumor suppressing role of PHGDH inhibitor CBR-5884 in epithelial ovarian cancer via regulating the ROS level and the downstream Wnt/β-catenin signaling pathway. What’s more, we concluded that CBR-5884 played a synergistic role with PARP inhibitor olaparib. In the future, we will promote the exploration about molecular targeted therapy based on PHGDH to prevent or reverse epithelial ovarian cancer and ovarian cancer cisplatin resistance in clinical.

5. Conclusion

In conclusion, our study demonstrated that PHGDH inhibitor CBR-5884 inhibits epithelial ovarian cancer proliferation, migration, and invasion through activating ROS/Wnt/β-catenin pathway and plays a synergistic role with PARP inhibitor olaparib. These provided a theoretical basis for PHGDH inhibitor CBR-5884 in clinical treatment.

Abbreviations

OC: Ovarian cancer  
EOC: Epithelial ovarian cancer  
PHGDH: Phosphoglycerate dehydrogenase  
ROS: Reactive oxygen species  
NAC: N-acetylcysteine  
CCK-8: Cell counting kit-8  
FBS: Fetal bovine serum  
OD450: Optical density at 450 nm  
PI: Propidium iodide  
LDH: Lactate dehydrogenase  
GSH: Glutathione  
SPF: Specific pathogen-free  
IHC: Immunohistochemistry  
DAB: Diaminobenzidine.

Data Availability

The results data used to support the findings of this study are included within the article.

Ethical Approval

This study was carried out in accordance with the standards of the Helsinki Declaration of the World Medical Association and approved by the Ethics Committee of China Medical University. All clinical samples were collected from the Shengjing Hospital of China Medical University with informed consent from all patients.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Xiaocui Zhang and Qing Yang put forward the study. Xiaocui Zhang and Meige Sun conducted the experiments and analyzed the data. Xiaocui Zhang and Yisheng Jiao drafted manuscript. Qing Yang and Bei Lin revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No.81872125), the Key Research and Development Program of Liaoning Province, China (NO.2018225062), and Outstanding Scientific Fund of Shengjing Hospital (No. 201704).

Supplementary Materials

Supplementary Table 1. PHGDH expression level in different cell lines from CCLE database. (Supplementary Materials)

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] S. Narod, “Can advanced-stage ovarian cancer be cured?,” Nature Reviews Clinical Oncology, vol. 13, no. 4, pp. 255–261, 2016.
[3] M. Malvezzi, G. Carioli, T. Rodriguez, E. Negri, and C. La Vecchia, “Global trends and predictions in ovarian cancer mortality,” Annals of Oncology, vol. 27, no. 11, pp. 2017–2025, 2016.
[4] U. A. Matulonis, A. K. Sood, L. Fallowfield, B. E. Howitt, J. Sehouli, and B. Y. Karlan, “Ovarian cancer,” Nature Reviews Disease primers, vol. 2, no. 1, article 16061, 2016.
[5] E. A. Eisenhauer, “Real-world evidence in the treatment of ovarian cancer,” Medical Oncology, vol. 28, supplement 8, 2017.
[6] D. Samanta and G. L. Semenza, “Serine synthesis helps hypoxic cancer stem cells regulate redox,” Cancer Research, vol. 76, no. 22, pp. 6458–6462, 2016.
[7] D. Samanta, Y. Park, S. A. Andrabi, L. M. Shelton, D. M. Gilkes, and G. L. Semenza, “PHGDH expression is required
for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis," Cancer Research, vol. 76, no. 15, pp. 4430–4442, 2022.

[11] H. Yoshino, N. Nohata, K. Miyamoto et al., "PHGDH as a key enzyme for serine biosynthesis in HIF2alpha-targeting therapy for renal cell carcinoma," Cancer Research, vol. 77, no. 22, pp. 6321–6329, 2017.

[12] S. Liu, Y. Sun, M. Jiang et al., "Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphorylglycerate dehydrogenase," Hepatology, vol. 66, no. 2, pp. 631–645, 2017.

[13] G. M. DeNicola, P. H. Chen, E. Mullarky et al., "NRF2 regulates serine biosynthesis in non-small cell lung cancer," Nature Genetics, vol. 47, no. 12, pp. 1475–1481, 2015.

[14] A. Fenner, "PHGDH is key for targeting HIF in RCC," Nature Reviews Urology, vol. 14, no. 12, p. 702, 2017.

[15] J. Chen, C. Solomides, H. Parekh, F. Simpkins, and H. Simpkins, "Cisplatin resistance in human cervical, ovarian and lung cancer cells," Cancer Chemotherapy and Pharmacology, vol. 75, no. 6, pp. 1217–1227, 2015.

[16] A. Barreiro-Alonso, M. Lamas-Maceiras, E. Rodriguez-Belmonte, A. Vizoso-Vazquez, M. Quindos, and M. E. Cerdan, "High mobility group B proteins, their partners, and other redox sensors in ovarian and prostate cancer," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5845061, 17 pages, 2016.

[17] J. N. Moloney and T. G. Cotter, "ROS signalling in the biology of cancer," Seminars in Cell & Developmental Biology, vol. 80, pp. 50–64, 2018.

[18] F. Bi, Y. An, T. Sun, Y. You, and Q. Yang, "PHGDH is upregulated at translational level and implicated in platin-resistant in ovarian cancer cells," Frontiers in Oncology, vol. 11, article 643129, 2021.

[19] E. Mullarky, N. C. Lucky, R. Beheshti Zavareh et al., "Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers," Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 7, pp. 1778–1783, 2016.

[20] A. L. Engel, N. I. Lorenz, K. Klann et al., "Serine-dependent redox homeostasis regulates glioblastoma cell survival," British Journal of Cancer, vol. 122, no. 9, pp. 1391–1398, 2020.

[21] L. Shen, P. Hu, Y. Zhang et al., "Serine metabolism antagonizes antiviral innate immunity by preventing ATP6V0d2-mediated YAP lysosomal degradation," Cell Metabolism, vol. 33, no. 5, pp. 971–987.e6, 2021.

[22] T. Zhang, M. C. Gillies, M. C. Madigan et al., "Disruption of De novo serine synthesis in Müller cells induces mitochondrial dysfunction and aggravated oxidative damage," Molecular Neurobiology, vol. 55, no. 8, pp. 7025–7037, 2018.

[23] X. Zhao, J. Fu, W. Tang, L. Yu, and W. Xu, "Inhibition of serine metabolism promotes resistance to cisplatin in gastric cancer," Onco Targets and Therapy, vol. 3, pp. 4833–4842, 2020.

[24] T. Catalano, E. D’Amico, C. Moscatello et al., "oxidative distress induces Wnt/bcatenin pathway modulation in colorectal cancer cells: perspectives on APC retained functions," Cancers, vol. 13, no. 23, p. 6045, 2021.

[25] Y. N. Wang, T. T. Jia, Y. Feng et al., "Hyperlipidemia impairs osseointegration via the ROS/Wnt/b-catenin pathway," Journal of Dental Research, vol. 100, no. 6, pp. 658–665, 2021.

[26] M. H. Elbatreek, M. P. Pachado, A. Cuadrado, K. Jandeleit-Dahm, and H. Schmidt, "Reactive oxygen comes of age: mechanism-based therapy of diabetic end-organ damage," Trends in Endocrinology and Metabolism: TEM, vol. 30, no. 5, pp. 312–327, 2019.

[27] W. Deng, Y. Wang, S. Zhao et al., "MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway," Journal of Cellular and Molecular Medicine, vol. 22, no. 6, pp. 3108–3118, 2018.

[28] N. Hirata, S. Yamada, Y. Sekino, and Y. Kanda, "Tobacco nitrosamine NNK increases ALDH-positive cells via ROS-Wnt signaling pathway in A549 human lung cancer cells," The Journal of Toxicological Sciences, vol. 42, no. 2, pp. 193–204, 2017.

[29] B. Li, Y. Cao, G. Meng et al., "Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway," ebioMedicine, vol. 39, pp. 239–254, 2019.

[30] H. Li, J. Chen, J. Liu et al., "CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/b-catenin-induced glycolytic metabolism," Experimental Cell Research, vol. 409, no. 1, article 112892, 2021.

[31] C. Zhang, L. Huang, J. Xiong et al., "Isosaltolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway," PLoS one, vol. 16, no. 3, article e0247752, 2021.

[32] D. Slade, "PARP and PARG inhibitors in cancer treatment," Genes & Development, vol. 34, no. 5-6, pp. 360–394, 2020.

[33] E. J. Llampert, A. Zimmer, M. Padget et al., "Combination of PARP inhibitor olaparib, and PD-L1 inhibitor Durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study," Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 26, no. 16, pp. 4268–4279, 2020.

[34] K. Moore, N. Colombo, G. Scambia et al., "Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer," The New England Journal of Medicine, vol. 379, no. 26, pp. 2495–2505, 2018.

[35] I. Ray-Coquard, P. Pautier, S. Pignata et al., "Olaparib plus bevacizumab as first-line maintenance in ovarian cancer," The New England Journal of Medicine, vol. 381, no. 25, pp. 2416–2428, 2019.

[36] M. Shan, J. Qin, F. Jin et al., "Autophagy suppresses isoprenaline-induced M2 macrophage polarization via the ROS/ERK and mTOR signaling pathway," Free Radical Biology & Medicine, vol. 110, pp. 432–443, 2017.

[37] S. F. Wang, M. S. Chen, Y. C. Chou et al., "Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2alpha-ATF4-CHSCT pathway," OncoTarget, vol. 7, no. 45, pp. 74132–74151, 2016.

[38] M. Popa, V. Fosse, K. Kleinmanns, L. Björgø, and E. McCormack, "Xenograft models of ovarian cancer for therapy evaluation," Methods in Molecular Biology (Clifton, NJ), vol. 2424, pp. 275–293, 2022.

[39] S. Mittal, P. Gupta, P. Chaluvally-Raghavan, and S. Pradeep, "Establishment of in vivo ovarian cancer mouse models using intraperitoneal tumor cell injection," Methods in Molecular Biology (Clifton, NJ), vol. 2424, pp. 247–254, 2022.

[40] C. Park, S. J. M. Cho, S. J. Park, S. H. Ko, S. B. Lee, and I. Y. Kim, "Bortezomib resistance in multiple myeloma is associated with increased serine synthesis," Cancer & Metabolism, vol. 5, no. 1, 2017.
[41] K. C. Ross, A. J. Andrews, C. D. Marion, T. J. Yen, and V. Bhattacharjee, "Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells," Molecular Cancer Therapeutics, vol. 16, no. 8, pp. 1596–1609, 2017.

[42] B. Zhang, A. Zheng, P. Hydbring et al., "PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis," Cell Reports, vol. 19, no. 11, pp. 2289–2303, 2017.

[43] J. Zhu, J. Ma, X. Wang et al., "High expression of PHGDH predicts poor prognosis in non-small cell lung cancer," Translational Oncology, vol. 9, no. 6, pp. 592–599, 2016.

[44] Z. Song, C. Feng, Y. Lu, Y. Lin, and C. Dong, "PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer," Gene, vol. 642, pp. 43–50, 2018.

[45] H. Wu, Y. Wang, M. Ying, C. Jin, J. Li, and X. Hu, "Lactate dehydrogenases amplify reactive oxygen species in cancer cells in response to oxidative stimuli," Signal Transduction and Targeted Therapy, vol. 6, no. 1, p. 242, 2021.

[46] H. Zhou, X. Lu, C. Du et al., "Cycloacceleration of Reactive Oxygen Species Generation Based on Exceedingly Small Magnetic Iron Oxide Nanoparticles for Tumor Ferroptosis Therapy," in Small, p. e2202705, Wiley, Weinheim an der Bergstrasse, Germany, 2022.

[47] L. Jin, K. M. Kiang, S. Y. Cheng, and G. K. Leung, "Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma," Laboratory Investigation, vol. 102, no. 2, pp. 194–203, 2022.

[48] Q. Li, J. Qiu, H. Yang et al., "Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma," Cancer Letters, vol. 482, pp. 112–125, 2020.

[49] X. Wu, J. Xia, J. Zhang et al., "Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma," British Journal of Haematology, vol. 190, no. 1, pp. 52–66, 2020.

[50] X. Zhang and W. Bai, "Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin," Cancer Chemotherapy and Pharmacology, vol. 78, no. 3, pp. 655–659, 2016.